Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 14–Jun 21, 2026)
OSTX dominates this week’s catalyst calendar with three trial readouts spanning solid tumors and hematologic malignancies, including a promising CAR-T study in relapsed AML. The week offers a lighter schedule overall, with only one distant PDUFA date for ACHV’s nicotine dependence treatment in mid-2026.
💊 FDA Decisions (PDUFA Dates)
| Date | Ticker | Drug | Indication | Type |
|---|---|---|---|---|
| 2026-06-20 | ACHV | — | nicotine dependence | NDA |
🧪 Trial Catalysts & Milestones
- OSTX — 2026-06-15: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Tre
- OSTX — 2026-06-15: Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
- OSTX — 2026-06-18: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzu
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- UNCY — NDA in 15 days, score 72/100
- IBRX — Phase 2 — Recruiting in 17 days, score 55/100
- AXSM — Phase 2 — Recruiting in 17 days, score 53/100
📈 Last Week’s Biggest Gainers
- TNGX +52.97% (volume 6.5x average)
- NUVL +39.28% (volume 77.0x average)
- ALHC +25.08% (volume 3.4x average)
- FRMI +22.60% (volume 3.5x average)
- YSS +22.09% (volume 1.0x average)
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.